News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arch Biopartners Inc. Scientists Identify Key Pathways and Therapeutic Targets in Kidney Disease and C. difficile Colitis


8/10/2010 8:58:09 AM

TORONTO, ONTARIO--(Marketwire - August 10, 2010) - Arch Biopartners Inc ("Arch" or the "Company")(CNSX: ACH) announces that Arch scientists have reported findings that identify key inflammation pathways in chronic kidney disease and C. difficile colitis.

The studies are the result of the scientists' ongoing research at the University of Calgary and are reported in the journals Gastroenterology and The Journal of the American Society of Nephrology.

Dr. Daniel Muruve, a principal scientist of Arch and co-author of the three papers, stated: "These findings are a key step in the Company's ongoing development of therapeutics for chronic kidney disease and C. difficile colitis."

Chronic kidney disease affects approximately 5-10% of the population in North America with annual health care costs in excess of 50 billion dollars. Patients with chronic kidney disease are at increased risk of heart disease, stroke and all-cause mortality. Currently there are very few specific treatments for patients with chronic kidney disease. Dr. Daniel Muruve and colleagues have identified important inflammatory pathways that cause chronic kidney damage. The paper by Vilaysane et al can be found at http://jasn.asnjournals.org/cgi/content/abstract/ASN.2010020143v1.

C. difficile are extremely toxic, super bacteria that are responsible for recent outbreaks and the majority of cases of hospital acquired diarrhea and inflammatory colitis. C. difficile are easily spread among hospitalized patients increasing the risk of major medical and surgical complications including death. C. difficile associated diseases increase the cost of health care by billions of dollars worldwide. Dr. Beck, Dr. Justin MacDonald and colleagues have identified two important pathways that control the host response to C. difficile infection in the gut. Papers by Ng et al and Hirota et al can be found at: http://www.gastrojournal.org/article/S0016-5085%2810%2900551-2/abstract and http://www.gastrojournal.org/article/S0016-5085%2810%2900470-1/abstract.

About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.

For more information on the Company, please consult the other public documents including all press releases, management information circular, financial statements and management discussion and analysis filed on SEDAR at www.sedar.com. The company's website address is www.archbiopartners.com.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.


Contacts:
Arch Biopartners Inc.
Richard Muruve
CEO
(647) 428-7031


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES